These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31423377)

  • 1. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome.
    Kumar B; Shah MAA; Kumar R; Kumar J; Memon A
    Cureus; 2019 Jun; 11(6):e4898. PubMed ID: 31423377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome.
    Umrani S; Jamshed W; Rizwan A
    Cureus; 2020 Nov; 12(11):e11760. PubMed ID: 33409009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome.
    Khurana S; Gupta S; Bhalla H; Nandwani S; Gupta V
    J Pharmacol Pharmacother; 2015; 6(3):130-5. PubMed ID: 26311995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.
    Roy D; Mahapatra T; Manna K; Kar A; Rana MS; Roy A; Bose PK; Banerjee B; Paul S; Chakraborty S
    PLoS One; 2020; 15(5):e0233230. PubMed ID: 32428019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
    Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
    Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.
    Nidorf M; Thompson PL
    Am J Cardiol; 2007 Mar; 99(6):805-7. PubMed ID: 17350370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
    Su JZ; Xue Y; Cai WQ; Huang QY; Chai DJ; Chen GL; Wang FB; Chen XP; Zhang DS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Sep; 39(9):807-11. PubMed ID: 22321227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients.
    Sindhu S; Singh HK; Salman MT; Fatima J; Verma VK
    J Pharmacol Pharmacother; 2011 Oct; 2(4):261-5. PubMed ID: 22025854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: A 12-week, open-label, pilot study.
    Yoshino G; Tanaka M; Nakano S; Matsumoto T; Kojima M; Murakami E; Morita T
    Curr Ther Res Clin Exp; 2009 Dec; 70(6):439-48. PubMed ID: 24692836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study.
    Toso A; Leoncini M; Magnaghi G; Biagini F; Martini O; Maioli M; Villani S; Comeglio M; Bellandi F
    J Cardiovasc Med (Hagerstown); 2023 Jan; 24(1):52-58. PubMed ID: 36473121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Rosuvastatin in Contrast-Induced Acute Kidney Injury in the Elderly: Post Hoc Analysis of the PRATO-ACS Trial.
    Tropeano F; Leoncini M; Toso A; Maioli M; Dabizzi L; Biagini D; Villani S; Bellandi F
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):159-66. PubMed ID: 26307206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.